Market Overview

GW Pharmaceutical's Upcoming Epidiolex Data Has Relatively Low Bar for Success

Related GWPH
Insys, GW Pharmaceuticals Rise On Short Seller's Comments
Getting The Word Out To Cannabis Users: A Chat With BudgetWeed CEO Marlon Fuller

On Tuesday, Leerink reiterated an Outperform rating on GW Pharmaceuticals (NASDAQ: GWPH) and $79 price target.

Analyst Joseph Schwartz believes the “bar for success is relatively low” for upcoming Epidiolex data, based on the review of epilepsy trials. Schwartz went on to explain that 20 to 50 percent reduction in seizures versus placebo is generally good enough to approve add-on treatments.

In the second half of 2014, the company will start placebo-controlled proof-of-concept study followed by studies in Dravet and Lennox-Gastaut syndrome in 2015.

Shares closed up 1.5 percent to $66.19 in Tuesday's trading.

Posted-In: Joseph Schwartz LeerinkAnalyst Color Reiteration Analyst Ratings

 

Related Articles (GWPH)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters